MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS) today announced its financial results for the first quarter ended March 31, 2011.
“During the first quarter of 2011, we continued to make strong progress towards initiating the clinical trial for our Cologuard™ test, which detects both precancerous polyps and cancer”
Exact reported total revenues of $1.0 million for the first quarter of 2011, compared to total revenues of $1.3 million during the same period of 2010.
